Last updated: August 9, 2025
Introduction
Hydrocodone Polistirex and Chlorpheniramine Polistirex combination therapy is primarily prescribed for managing cough and upper respiratory symptoms associated with allergies and cold. The formulation involves extended-release mucoadhesive preparations, with hydrocodone serving as an opioid cough suppressant and chlorpheniramine acting as an antihistamine. These compounded formulations are manufactured through specialized processes, and reliable supplier identification is critical for pharmaceutical companies, healthcare providers, and regulatory agencies. This article provides a comprehensive overview of the primary suppliers, manufacturing landscape, and strategic considerations involved in sourcing these compounds.
Overview of Hydrocodone Polistirex and Chlorpheniramine Polistirex
Hydrocodone Polistirex is a sustained-release form of hydrocodone, a semi-synthetic opioid analgesic with cough suppressant properties (antitussive). When combined with chlorpheniramine polistirex, an extended-release antihistamine, it offers synergistic relief for coughs associated with allergic reactions. The polistirex in both compounds refers to a polymer-based sustained-release matrix that prolongs drug action, enabling less frequent dosing.
Although these formulations are marketed under various brand names, the supply chain for raw materials and excipients, as well as for finished dosage forms, involves multiple specialized suppliers. Regulatory authorities like the FDA oversee manufacturing standards, ensuring suppliers meet strict quality controls.
Key Suppliers for Hydrocodone Polistirex
-
Manufacturers of Hydrocodone Base and API
-
Mallinckrodt Pharmaceuticals
A leading supplier of opioid APIs, Mallinckrodt supplies hydrocodone API to licensed manufacturers worldwide. The company emphasizes compliance with US DEA regulations, and its hydrocodone APIs are used in various formulations, including polistirex-based extended-release products.
-
Amneal Pharmaceuticals
Known for a broad portfolio of APIs, Amneal produces hydrocodone API under rigorous quality standards and supplies to generic drug manufacturers globally.
-
Sun Pharmaceutical Industries
An Indian multinational, Sun Pharma supplies hydrocodone APIs for domestic US markets and exports. Their manufacturing facilities adhere to cGMP standards.
-
Indivior
As a specialized manufacturer of opioid products, Indivior supplies hydrocodone formulations and APIs for prescription medicines, including controlled-release versions.
-
Distribution and APIs Importers
Licensed distributors such as ALPS Pharmaceuticals and Fresenius Kabi facilitate the distribution of hydrocodone APIs within regulated markets, ensuring supply chain integrity.
Key Suppliers for Chlorpheniramine Polistirex
-
API Manufacturers
-
Hikma Pharmaceuticals
A major producer of chlorpheniramine maleate, their commercial API is used in extended-release formulations.
-
Mitsubishi Tanabe Pharma
Supplies chlorpheniramine APIs globally for compounded and manufactured medications.
-
Eprova AG (part of Novartis)
Produces high-quality chlorpheniramine APIs distributed across multiple markets.
-
Excipient and Polymer Suppliers for Polistirex Matrix
-
BASF
Supplies specific polymers used in the polistirex matrix, such as polyalkyl cyanoacrylate derivatives, which facilitate sustained release.
-
Dow Chemical
Offers excipients and polymers compatible with pharmaceutical formulations.
Manufacturers of Finished Extended-Release Formulations
While many generic formulations are compounded locally, several pharmaceutical manufacturers produce authorized extended-release hydrocodone chlorpheniramine products:
-
Mallinckrodt Pharmaceuticals – Proprietor of multiple controlled-release opioid products.
-
Teva Pharmaceuticals – Produces generic controlled-release opioid-antihistamine combinations.
-
Zydus Cadila – An Indian manufacturer that produces various extended-release formulations, often exporting to regulated markets.
-
Lannett Company – Engages in manufacturing generic hydrocodone containing products, including extended-release formulations.
Strategic Considerations in Supplier Selection
-
Regulatory Compliance and Quality Assurance
Ensuring API suppliers adhere to cGMP standards is paramount. Suppliers must have validated manufacturing processes and quality control systems aligned with FDA, EMA, or other regional regulatory standards.
-
Supply Chain Security and Reliability
Given the critical nature of opioid APIs, establishing robust supply agreements with multiple suppliers reduces risk of shortages. Suppliers with proven track records and transparent supply chains are preferred.
-
Pricing and Contract Flexibility
Pricing negotiations should account for the high costs associated with API production, especially for controlled substances. Long-term contracts may provide price stability.
-
Geopolitical Factors
Manufacturers from established jurisdictions—primarily the US, Europe, and India—offer diverse options. Political stability and export policies influence supplier viability.
Regulatory and Compliance Challenges
Obtaining APIs for hydrocodone, a Schedule II controlled substance in the US, involves complex regulatory hurdles. Suppliers must be registered with DEA and comply with stringent security, tracking, and reporting standards. The same applies to chlorpheniramine APIs, which are over-the-counter in many regions but require purity and quality compliance for formulation.
Supply chain transparency is vital to prevent diversion of controlled substances and ensure product integrity. Manufacturers often work with authorized distributors and maintain detailed audit trails.
Conclusion
The procurement landscape for Hydrocodone Polistirex and Chlorpheniramine Polistirex involves a tiered supply chain with leading manufacturers of APIs, excipients, and finished formulations. Notable primary suppliers include Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Mitsubishi Tanabe Pharma, and BASF. Strategic sourcing emphasizes regulatory compliance, supply chain robustness, and price stability.
Key Takeaways
-
Top API suppliers for hydrocodone include Mallinckrodt, Amneal, and Sun Pharma, while chlorpheniramine APIs are supplied by Hikma, Mitsubishi Tanabe, and Novartis.
-
Manufacturers of extended-release formulations predominantly include established players like Mallinckrodt, Teva, Zydus Cadila, and Lannett.
-
Ensuring regulatory compliance and supply chain security is crucial when sourcing APIs for controlled substances.
-
Polymer suppliers such as BASF and Dow are vital for manufacturing the polistirex matrix.
-
A diversified supplier portfolio mitigates risks associated with geopolitical, regulatory, or manufacturing disruptions.
FAQs
1. Are there generic alternatives to brand-name hydrocodone polistirex and chlorpheniramine polistirex?
Yes. Several generics exist, manufactured by companies like Teva and Zydus Cadila, offering cost-effective alternatives that meet regulatory standards in authorized markets.
2. How do regulatory agencies oversee suppliers of controlled substances like hydrocodone?
Agencies such as the FDA in the US and the EMA in Europe mandate strict registration, regular audits, and compliance with cGMP standards for suppliers handling Schedule II controlled substances.
3. Can I source these compounds directly from manufacturers abroad?
Sourcing directly is possible but complex due to regulatory restrictions, import licensing, and security requirements. Collaboration with authorized distributors is generally recommended.
4. What are common challenges in sourcing hydrocodone APIs?
Regulatory hurdles, export restrictions, demand fluctuations, and quality compliance are significant challenges impacting supply continuity.
5. How does the choice of supplier influence the quality and efficacy of hydrocodone polistirex formulations?
Suppliers with strict quality controls and compliant manufacturing processes ensure API purity, potency, and consistency, directly affecting clinical efficacy and safety.
References
[1] U.S. Food and Drug Administration. “Controls on Opioid APIs.” FDA, 2022.
[2] IMS Health. “Global API Market Report,” 2021.
[3] European Medicines Agency. “Overview of API Regulations,” 2022.
[4] Mallinckrodt Pharmaceuticals. “Product Portfolio,” 2023.
[5] Hikma Pharmaceuticals. “API Manufacturing Capabilities,” 2022.
